Evidence map›Paper›PMID 34626143›Full record

ArticleGlia2022

Blocking Kallikrein 6 promotes developmental myelination.

Hyesook Yoon, Erin M Triplet, Whitney L Simon, Chan-Il Choi, Laurel S Kleppe, Elena De Vita, Aubry K Miller, Isobel A Scarisbrick

Open access · greenAbstract read
In one paragraph

Article in Glia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Drug Discovery Strategies for Kallikrein-Related Peptidases.International journal of molecular sciences · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Spatiotemporal transcriptomic map of glial cell response in a mouse model of acute brain ischemia.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Hyesook YoonDepartment of Physical Medicine and Rehabilitation, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.
Erin M TripletRegenerative Sciences Program, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.
Whitney L SimonDepartment of Physical Medicine and Rehabilitation, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.
Chan-Il ChoiDepartment of Physical Medicine and Rehabilitation, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.
Laurel S KleppeDepartment of Physical Medicine and Rehabilitation, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.
Elena De VitaFaculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
Aubry K MillerCancer Drug Development Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Isobel A ScarisbrickDepartment of Physical Medicine and Rehabilitation, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, Minnesota, USA.ORCID 0000-0003-2395-589X
Mayo Clinic · USGerman Cancer Research Center · DE

Funding

Medical Scientist Traning Program at Mayo ClinicT32GM065841 · NIGMS · MAYO CLINIC ROCHESTER · PI KAUFMANN, SCOTT H, SCHIMMENTI, LISA A · 2003 to 2022
$5.8M
Role of Protease Activated Receptors in Spinal Cord Injury and RepairR01NS052741 · NINDS · MAYO CLINIC ROCHESTER · PI SCARISBRICK, ISOBEL A · 2008 to 2017
$3.6M
Targeting Protease Activated Receptor 1 for Repair of the Injured Spinal CordR01NS120877 · NINDS · MAYO CLINIC ROCHESTER · PI SCARISBRICK, ISOBEL A · 2021 to 2024
$1.9M
Regulatory Action of Protease Activated Receptor 1 in Myelin ProductionR21NS107946 · NINDS · MAYO CLINIC ROCHESTER · PI SCARISBRICK, ISOBEL A · 2019 to 2019
$437k
NIGMS NIH HHS T32 GM065841NINDS NIH HHS R01 NS052741NINDS NIH HHS R01 NS120877NINDS NIH HHS R21 NS107946
6 · The paper itself

Abstract

Kallikrein related peptidase 6 (Klk6) is a secreted serine protease highly expressed in oligodendrocytes and implicated in demyelinating conditions. To gain insights into the significance of Klk6 to oligodendrocyte biology, we investigated the impact of global Klk6 gene knockout on CNS developmental myelination using the spinal cord of male and female mice as a model. Results demonstrate that constitutive loss of Klk6 expression accelerates oligodendrocyte differentiation developmentally, including increases in the expression of myelin proteins such as MBP, PLP and CNPase, in the number of CC-1+ mature oligodendrocytes, and myelin thickness by the end of the first postnatal week. Co-ordinate elevations in the pro-myelinating signaling pathways ERK and AKT, expression of fatty acid 2-hydroxylase, and myelin regulatory transcription factor were also observed in the spinal cord of 7d Klk6 knockouts. LC/MS/MS quantification of spinal cord lipids showed sphingosine and sphingomyelins to be elevated in Klk6 knockouts at the peak of myelination. Oligodendrocyte progenitor cells (OPCs)-derived from Klk6 knockouts, or wild type OPCs-treated with a Klk6 inhibitor (DFKZ-251), also showed increased MBP and PLP. Moreover, inhibition of Klk6 in OPC cultures enhanced brain derived neurotrophic factor-driven differentiation. Altogether, these findings suggest that oligodendrocyte-derived Klk6 may operate as an autocrine or paracrine rheostat, or brake, on pro-myelinating signaling serving to regulate myelin homeostasis developmentally and in the adult. These findings document for the first time that inhibition of Klk6 globally, or specifically in oligodendrocyte progenitors, is a strategy to increase early stages of oligodendrocyte differentiation and myelin production in the CNS.

Indexed as

OligodendrogliaTandem Mass SpectrometryAnimalsCell DifferentiationFemaleKallikreinsMaleMiceMice, Inbred C57BLMyelin SheathKallikreinsPrss18 protein, mousebrain derived neurotrophic factorlipidoligodendrocytespinal cord

Identifiers

PMID34626143
PMCPMC8732303
OpenAlexW3204589994

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.